A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3,548

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

June 23, 2023

Study Completion Date

June 23, 2023

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

mRNA-1273.529

Sterile liquid for injection

BIOLOGICAL

mRNA-1273

Sterile liquid for injection

BIOLOGICAL

mRNA-1273.214

Sterile liquid for injection

Trial Locations (29)

AB25 2ZD

Aberdeen Royal Infirmary - PPDS, Aberdeen

BS10 5NB

Southmead Hospital, Bristol

PE8 6PL

Wansford and Kingscliffe Practice, Wansford

WA7 2DA

Halton General Hospital, Runcorn

TS4 3BW

The James Cook University Hospital, Middlesbrough

TR1 3LJ

Royal Cornwall Hospital, Truro

EX2 5DW

Royal Devon and Exeter Hospital NHS Trust, Exeter

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

GL1 3NN

Gloucester Royal Hospital, Gloucester

PO1 3HN

Portsmouth Research Hub, Portsmouth

FY3 7EN

Fylde Coast Clinical Research, Blackpool

LE5 4PW

Leicester General Hospital, Leicester

Unknown

Salford Royal Hospital - PPDS, Salford

WC1E 6EB

University College London Hospitals Covid-19 Vaccine Centre, London

HU16 5JQ

Castle Hill Hospital, Hull

TF1 6TF

The Princess Royal Hospital, Telford

BA1 3NG

Royal United Hospital, Bath

S5 7AU

Sheffield/Northern General Hospital, Sheffield

CF72 8XR

Royal Glamorgan Hospital - PPDS, Pont-y-clun

BD9 6RJ

Bradford Institute for Health Research, Bradford

SN3 6BB

Great Western Hospital, Swindon

B15 2TH

Queen Elizabeth Hospital, Birmingham

EC1A 7BE

Barts Hospital, London

NW3 2QG

Royal Free Hospital, London

SE5 9RS

Kings College Hospital, London

SW10 9NH

Chelsea and Westminster Hospital, London

SW17 0RE

St. George's Hospital, London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

PL6 8DH

Derriford Hospital, Plymouth

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY